Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

NCT00227617 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Neoplastic Syndrome
Neuroendocrine Tumor

Interventions

BIOLOGICAL: bevacizumab
DRUG: 5-fluorouracil
DRUG: leucovorin
DRUG: oxaliplatin

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]